Latest filing published 27 Aug 2026 for Abbott Laboratories, €5.8M.
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
At Abbott Laboratories, Robert B. Ford, Executive Vice President, sold 51 times, 48 of them with an amount, for EUR 29,993,110, with a median of EUR 20,375. The largest are EUR 10,795,870 on August 25, 2022, then EUR 8,411,265 and EUR 6,477,163, both on September 12, 2024. Six purchases total EUR 2,183,133, with a median of EUR 34,928, or 11% of market trades: EUR 1,713,342 on January 23, 2026, EUR 388,905 and EUR 47,796 on December 14, 2016.
The 111 filings, all at Abbott Laboratories, are published between February 23, 2016 and August 27, 2026. They include 27 grants, 11 option exercises and 16 filings of another kind.
The year 2018 dominates clearly, with 52 filings, ahead of 15 in 2016; 2023 has only 2. Seven filings, one purchase and 2 sales among them, fall within the last twelve months. Publication comes a median of 2 days after the transaction.
At Abbott Laboratories, 50 trades by Ford fall within 30 days of a trade by Brian J. Blaser, 46 of one by Daniel Gesua Sive Salvadori and 45 of one by Jaime Contreras, always in the same direction.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 111 declarations